Licensing & partnership

Vor Bio adds RemeGen's long-acting BAFF/APRIL blocker RC298 to its license

Vor Bio widened its licence from RemeGen to cover RC298, an early-stage long-acting blocker of both BAFF and APRIL, for markets beyond Greater China. Vor pays about $56 million upfront, $10 million of it in cash, plus development milestones of as much as $300 million. RemeGen will lead phase 1 after a planned China IND in early 2027.

Written by Gosset from public sources. Source types: Press release · SEC/exchange filing · News article. Sources are available to Gosset users. Log in to see them.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call